Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal Vaccination

2002 ◽  
Vol 22 (1_suppl) ◽  
pp. 58-66 ◽  
Author(s):  
Faruque Ahmed ◽  
Elamin E. Elbasha ◽  
Betsy L. Thompson ◽  
Jeffrey R. Harris ◽  
Vishnu-Priya Sneller
Keyword(s):  
Cost Benefit Analysis ◽  
Pneumococcal Vaccination ◽  
Cost Benefit ◽  
Performance Measure ◽  
Benefit Analysis ◽  
Economic Implications ◽  
The Status ◽  
Markov Decision ◽  
Information Set ◽  
Markov Decision Model

Objectives Measurement of the quality of care provided by managed care organizations (MCOs) has achieved national prominence, though there is controversy regarding its value. This article assesses the economic implications of a new Health Plan Employer Data and Information Set (HEDIS®) measure for pneumococcal vaccination. Methods A Markov decision model, with Monte Carlo simulations, was utilized to conduct a cost-benefit analysis of annual HEDIS-associated interventions, which were repeated for 5 consecutive years, in an average Medicare MCO, using a societal perspective and a 3% annual discount rate. Results Compared with the status quo, the HEDIS intervention will be cost saving 99.8% of the time, with an average net savings of $3.80 per enrollee (95% probability interval: $0.73–$6.87). Conclusions The new HEDIS measure will save societal dollars. This type of analysis is essential if performance measurement is to become a legitimate part of our health care landscape.

scholarly journals Test and Treat in Washington, DC: Evaluating the Costs and Benefits of a Comprehensive Strategy to Fight HIV/AIDS

2014 ◽  
Vol 21 ◽  
pp. 7
Author(s):  
Estelle R. Raimondo
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Status Quo ◽  
Washington Dc ◽  
Benefit Analysis ◽  
Costs And Benefits ◽  
Comprehensive Strategy ◽  
Economic Implications ◽  
The Status ◽  
Hiv Aids

This paper assesses the economic implications of an innovative approach to preventing the spread of HIV/AIDS in Washington, DC. “Test & Treat” is premised on the idea that the epidemic can ultimately be eliminated by testing people widely and regularly and by putting all infected persons on antiretroviral medicines upon diagnosis. The relative costs and benefits of Test & Treat are quantified, monetized, and compared to the status quo, which can be characterized as a ‘test and wait’ approach. This cost-benefit analysis concludes that under a plausible set of circumstances, and with a conservative estimate of the number of infections averted, the benefits of Test & Treat in Washington, DC would outweigh the costs of implementation.

Resilience in social and economic systems: a concept that fails the cost–benefit test?

1998 ◽  
Vol 3 (2) ◽  
pp. 221-262 ◽  
Author(s):  
NICK HANLEY
Keyword(s):  
Cost Benefit Analysis ◽  
Social Systems ◽  
Cost Benefit ◽  
Status Quo ◽  
Economic Systems ◽  
Benefit Analysis ◽  
Ecological Concept ◽  
The Status ◽  
The Subject ◽  
The Cost

One of the first lessons that students of cost-benefit analysis (CBA) learn is to ask whether projects or policies which they are studying generate additional benefits or costs, relative to the status quo. They are also told to be very careful in defining the project/policy which is the subject of their analysis. In my view, the ecological concept of resilience fails the CBA test, when applied to the study of economic and social systems, because it offers no additional insights to those we have already, and appears to be poorly defined.

The Economic Implications of a Reusable Flexible Digital Ureteroscope: A Cost-Benefit Analysis

2017 ◽  
Vol 197 (3 Part 1) ◽  
pp. 730-735 ◽  
Author(s):  
Christopher J. Martin ◽  
Sean B. McAdams ◽  
Haidar Abdul-Muhsin ◽  
Victoria M. Lim ◽  
Rafael Nunez-Nateras ◽  
...  
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Economic Implications

scholarly journals Investigating ADS-B MOPS Compliance using Open Data

10.29007/q4kb ◽  
2019 ◽  
Author(s):  
Enrico Spinielli
Keyword(s):  
Cost Benefit Analysis ◽  
Open Data ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Active Interrogation ◽  
Free Data ◽  
The Us ◽  
The Status ◽  
Order Of Magnitude ◽  
The Cost

The introduction of Automatic Dependent Surveillance-Broadcast (ADS-B) in Aviation as mandated in the US [3,4] and in Europe [1,2] rests on the (at least theoretical) benefits of the switch of paradigm in ATC surveillance from (continuously) active interrogation of aircraft positions by primary radars to (almost always) automatic broadcast of data by the aircraft. The cost/benefit analysis in favour of this shift weights on the 1) higher frequency and precision of the aircraft information (position, speed, . . . ) made available to ATC/neighbouring aircraft leading to increased safety and increased airspace capacity and 2) on the (at least one) order of magnitude reduction in ground infrastructure costs [5]. Infrastructure needs nontheless to be deployed both on the ground and in the air; and in the end it is the passenger who pays via taxes on tickets or airports services: so what is the status of deployment? This paper investigates, using only open and free data, the status of compliance of aircraft in the European airspace, i.e. how many aircraft flying in Europe comply to the EASA ADS-B mandate.

Persuasion and Economic Efficiency: The Cost-Benefit Analysis of Banning Abortion

1993 ◽  
Vol 9 (2) ◽  
pp. 229-252 ◽  
Author(s):  
Julianne Nelson
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Status Quo ◽  
Benefit Analysis ◽  
Pareto Improvement ◽  
Net Benefit ◽  
Policy Debates ◽  
The Status ◽  
The One ◽  
The Cost

How do economists persuade their readers that one policy is superior to another? A glance at the literature on welfare economics quickly provides the answer to this question: Economists enter policy debates armed with mathematical models, evaluating options on the basis of their consequences. Economists typically classify a policy change as a welfare (or “potential Pareto”) improvement with respect to the status quo if the gain realized by the winners exceeds the harm sustained by the losers. The best policy becomes the one that generates the highest net benefit.

Cost Effectiveness and Cost Benefit of Vaccination Against Pneumococcal Pneumonia. Implications for Clinical Practice

1982 ◽  
Vol 3 (4) ◽  
pp. 299-302 ◽  
Author(s):  
Jane Sisk Willems
Keyword(s):  
Health Care ◽  
Clinical Practice ◽  
Cost Effectiveness ◽  
Pneumococcal Pneumonia ◽  
Cost Benefit Analysis ◽  
Pneumococcal Vaccination ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Cost Of Treatment ◽  
The Cost

AbstractThe economic techniques of cost-effectiveness and cost-benefit analysis have provided useful insights into the potential advantages of vaccination against pneumococcal pneumonia. They suggest that the cost of vaccinating persons 65 years and older and perhaps younger persons with high risk conditions would be reasonable when compared with the cost of treatment for pneumococcal pneumonia. These findings, together with other considerations, may guide physicians and health care policymakers in deciding which individuals might be expected to benefit from pneumococcal vaccination.

Sign in / Sign up

Export Citation Format

Share Document